FOXO4-DRI

Overview

A synthetic D-retro-inverso peptide designed to disrupt the FOXO4–p53 interaction and selectively trigger apoptosis in senescent cells (a 'senolytic'). Entirely experimental; no human trials.

Mechanism of Action

Interferes with FOXO4 binding to p53 in senescent cells, releasing p53 to induce targeted apoptosis — demonstrated in mouse models of aging.

Research Summary

Single influential 2017 mouse study (Baar et al., Cell) plus preclinical follow-ups. No human safety or efficacy data.

Vendors selling FOXO4-DRI

Scored vendors carrying FOXO4-DRI, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Prescribers who offer FOXO4-DRI

3 prescribers in our directory work with FOXO4-DRI, each confirmed from their own website. Peptides like FOXO4-DRI require a prescription from a licensed provider.

Reported Side Effects

• Unknown in humans

Frequently asked questions

Has FOXO4-DRI been independently lab-tested?

Disclosed Labs has collected 14 Certificates of Analysis (COA) for FOXO4-DRI from 7 independent testing labs. 10 vendors have submitted material for testing. Products average 99.8% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/fox04-dri/testing.

What is the average purity of FOXO4-DRI on the market?

Based on 14 COAs analyzed by Disclosed Labs, FOXO4-DRI products average 99.8% (±0.2%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/fox04-dri/coas.

Where can researchers source FOXO4-DRI?

3 vendors with Disclosed Labs trust grades currently list FOXO4-DRI, including OROS Research, Peptide Tech, Certified Peptides. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/fox04-dri.

Which prescribers offer FOXO4-DRI with a prescription?

3 prescribers in the Disclosed Labs directory work with FOXO4-DRI, each confirmed from their own website. FOXO4-DRI requires a prescription from a licensed provider. Browse them at https://www.disclosedlabs.com/prescribers?peptide=FOXO4-DRI.

How does FOXO4-DRI work?

Interferes with FOXO4 binding to p53 in senescent cells, releasing p53 to induce targeted apoptosis — demonstrated in mouse models of aging.

What does the research say about FOXO4-DRI?

Single influential 2017 mouse study (Baar et al., Cell) plus preclinical follow-ups. No human safety or efficacy data.